Immutep Reports Promising Breast Cancer Trial Results
Company Announcements

Immutep Reports Promising Breast Cancer Trial Results

Immutep Ltd (AU:IMM) has released an update.

Immutep Ltd reports promising results from a Phase II/III trial of its immunotherapy drug eftilagimod alpha (efti) in combination with paclitaxel for treating metastatic breast cancer, with a 50% overall response rate and a complete response in a patient who had been refractory to multiple therapies. The high-dose 90mg treatment, presented at ESMO Breast Cancer 2024 Congress, was well-tolerated with a favorable safety profile, and further data is expected in CY2024. The trial is part of the FDA’s Project Optimus initiative to optimize dosing for better efficacy and safety outcomes.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmutep reports Q1 cash receipts from custmers $20,000
TipRanks Australian Auto-Generated NewsdeskImmutep Ltd Reports Positive Advances in Cancer Trials
TipRanks Australian Auto-Generated NewsdeskImmutep Limited Announces 2024 AGM Details
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App